MYB and leukemia: In vivo ATRA treatment in secondary recipients of Cdkn2a-WT MYB::PLEKHO1 or Cdkn2a-KO MYB::PLEKHO1 leukemias resulted in a significant reduction in disease burden (Figure 6B and Supplemental Figure 7A).